tbuckley/cabot-search huggingface dataset:
THU0522 Increasing Incidence of Gout in Western Sweden – A Register Study
Authors: M.I. Dehlin, P. Drivelegka, V. Sigurdardottir, A. Svärd, L. Jacobsson
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gout is the most common inflammatory arthritic disease worldwide. The prevalence varies due to cultural, ethnical and genetic differences in populations, which emphasizes the need for national/regional data on occurrence. While there are several studies on the prevalence of gout only few have addressed the incidence of gout and there are no contemporary studies in Sweden and the neighbouring Nordic countries. <h3>Objectives</h3> In the present study we measured the incidence of gout in 2012 and its trends from 2004 to 2012 in the Western Swedish Health Care Region (WSHCR) in Sweden. <h3>Methods</h3> We identified all incident cases of gout from 2004 through 2012 through VEGA, a diagnosis register covering all visits to physicians in primary and secondary care and hospitalizations in WSHCR. WSHCR has 1 600 000 inhabitants, roughly 20% of the population of Sweden, and is representative for the country as a whole with regard to demographics and health status. For the analyses of incidence trends an incident case of gout was defined as having a visit with a first ICD-10 diagnosis of gout (M10, M14) not preceded by a diagnosis of gout for the three calendar years before. Cumulative incidence per year was calculated using the number of incident gout cases aged 20 and above by calendar year (from 2004 to 2012) as the numerator and the total person-years aged 20 and above of WSHCR by the end of each year as the denominator. We calculated standardized estimates (direct method) using the whole Swedish population aged ≥20 years in 2012 as standard population Calculation of incidence trend was performed using logistic regression. Incidence in 2012 was based on cases with their first diagnosis of gout 2012 without any such diagnosis during the12 preceding years (2000–2011). All cases were linked to Statistics Sweden (for death and possible emigration before Dec 2012). <h3>Results</h3> The incidence of gout increased steadily and significantly (p for trend &lt;0.001) from 2004 to 2012 with a 50% increase in the total population. The male to female ratio of gout incidence was consistently two to three fold from 2004 to 2012 (Fig. 1). The incidence of gout in Sweden 2012 was 190 cases per 100 000 person-years. <h3>Conclusions</h3> Gout is an increasing health care problem all over the world and also in western Sweden where the incidence of gout increased significantly over the last decade being approximately three times higher than that for rheumatoid arthritis. This increase might reflect changes in the disease panoramic and cultural changes. <h3>Disclosure of Interest</h3> None declared
Platelets from Sickle Cell Disease Individuals Demonstrate Increased Adhesive Properties That Are Reversed by Hydroxyurea Therapy in Association with Alterations in Intraplatelet cAMP and αIIbα3 Integrin Activation
Authors: Renata P. Ferreira, Carla F. Franco-Penteado, Sara T.O. Saad, Fernando F. Costa, Nicola Conran
Journal: Blood (2008)
Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials
Authors: Yuko Tanabe, Hitoshi Ichikawa, Takashi Kohno, Hiroshi Yoshida, Takashi Kubo, Mamoru Kato, Satoru Iwasa, Atsushi Ochiai, Noboru Yamamoto, Yasuhiro Fujiwara, Kenji Tamura
Journal: Molecular Cancer (2016)

It is still controversial whether comprehensive genome screening of target molecules by next generation sequencing (NGS) is needed to increase clinical efficacy of investigational drugs or accelerate drug development, although several studies are being carried out. Therefore, we performed a prospective study to evaluate the feasibility of comprehensive gene screening in this setting. Our findings indicate that actionable alterations were identified in 45% of the analyzed patients, most frequently in those with breast cancer. Common actionable alterations were found in PIK3CA mutation, BRCA2 mutation, ERBB2 amplification, and CCND1 amplification. In total, 22% of the analyzed patients could be entered into phase I clinical trials, and 8% of them were treated with "matched" drugs. Among patients who received matched therapies, response and disease control rates were 33 and 78%, respectively. On the other hand, in the patients who received "non-matched" therapy, the objective response rate was 6%. We believe this data indicates that NGS-based molecular pre-screening is a potent platform for use before patient entry into phase I trials.
THU0389 Comparing Diffusion Weighted Imaging (DWI) with Clinical Parameters and Short Tau Inversion Recovery (STIR) Sequence in Detecting Spinal and Sacroiliiac (SI) Joints Inflamation in Spondyloarthritis (SPA)
Authors: H.Y. Chung, C.S. Lau, P. Li
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> DWI has been proposed for SpA diagnosis and disease monitoring1,2. The clinical correlation and effectiveness of this imaging when compared to the traditional STIR sequence is still under evaluation. <h3>Objectives</h3> To compare DWI with with clinical features, and traditional STIR sequence in detecting spinal and SI joints inflamation in SpA patients. <h3>Methods</h3> One hundred and ten patients fulfilled ASAS Axial SpA criteria were recruited consecutively from two rheumatology centers in Hong Kong. Clinical, radiological and blood parameters were collected. DWI and STIR MRI were performed simultaneously and results were scored according to the Spondyloarthritis Research Consortium of Canada (SPARCC) for comparison. The Apparent Diffusion Coefficient (ADC) values were also calculated. <h3>Results</h3> DWI showed no correlation with clinical features. When compare with STIR sequence, it correlated well with STIR sequence at the SI joints level (CC 0.76, p&lt;0.001), but weakly at the spinal level (CC 0.23, p=0.02). At SI joints level, presence of inflammation by both STIR sequence and DWI were associated with increase in maximum (B=0.24, p=0.02 in STIR; B=0.37, p&lt;0.001 in DWI) and mean ADC values (B=0.17, p=0.003 in STIR; B=0.15, p=0.01 in DWI). Maximum (B=0.19, p=0.04) and mean spinal ADC values (B=0.18, p=0.01) were also positively associated with DWI detected spinal inflammation. STIR sequence had no association with ADC values. Presenec of Modic lesion showed positive correlation with STIR (B=7.12, p=0.01) but not spinal ADC values. <h3>Conclusions</h3> Both STIR sequence and DWI perform similiarily in detecting active sacroiliitis. At spinal level, ADC values appear to be independent of other imaging/ clinical assessment and are not affected by degenerations. <h3>References</h3> Gaspersic N, Sersa I, Jevtic V, et al. Monitoring ankylosing spondylitis therapy by dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging. Skeletal Radiol. 2008 Feb; 37(2): 123–31. Sahin N, Hacibeyoglu H, Ince O, et al. Is there a role for DWI in the diagnosis of sacroiliitis based on ASAS criteria? Int J Clin Exp Med. 2015 May 15; 8(5): 7544–52. <h3>Disclosure of Interest</h3> None declared
FLT3-ITD but Not FLT3-TKD Mutations Have Major Prognostic Impact in Normal Karyotype AML.
Authors: Stephanie Schneider, Friederike Schneider, Annika Dufour, Gudrun Mellert, Evelyn Zellmeier, Jan Braess, Stefan K. Bohlander, Michaela Feuring-Buske, Christian Buske, Susanne Fritsch, Achim Heinecke, Maria C. Sauerland, Eva Hoster, Michael Unterhalt, Wolfgang E. Berdel, Bernhard J. Wormann, Thomas Buechner, Wolfgang Hiddemann, Karsten Spiekermann
Journal: Blood (2007)
Identification and Characterization of New Microrna Biomarkers and Target Genes in Drug-Insensitive CD34+ CML Stem/Progenitor Cells Using Global Comparative RNA-Seq Analyses
Authors: Hanyang Lin, Jonathan Zeng, Katharina Rothe, Jens Ruschmann, Oleh Petriv, Kieran O'Neill, Tobias Maetzig, David Knapp, Ryan R. Brinkman, Inanc Birol, Donna L. Forrest, Carl Hansen, Connie J. Eaves, R. Keith Humphries, Xiaoyan Jiang
Journal: Blood (2015)
BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection—Implications for Oncolytic Viral Therapy
Authors: Chelsea Bolyard, W. Hans Meisen, Yeshavanth Banasavadi-Siddegowda, Jayson Hardcastle, Ji Young Yoo, Eric S. Wohleb, Jeffrey Wojton, Jun-Ge Yu, Samuel Dubin, Maninder Khosla, Bo Xu, Jonathan Smith, Christopher Alvarez-Breckenridge, Pete Pow-anpongkul, Flavia Pichiorri, Jianying Zhang, Matthew Old, Dan Zhu, Erwin G. Van Meir, Jonathan P. Godbout, Michael A. Caligiuri, Jianhua Yu, Balveen Kaur
Journal: Clinical Cancer Research (2016)

Purpose: Brain angiogenesis inhibitor (BAI1) facilitates phagocytosis and bacterial pathogen clearance by macrophages; however, its role in viral infections is unknown. Here, we examined the role of BAI1, and its N-terminal cleavage fragment (Vstat120) in antiviral macrophage responses to oncolytic herpes simplex virus (oHSV).Experimental Design: Changes in infiltration and activation of monocytic and microglial cells after treatment of glioma-bearing mice brains with a control (rHSVQ1) or Vstat120-expressing (RAMBO) oHSV was analyzed using flow cytometry. Co-culture of infected glioma cells with macrophages or microglia was used to examine antiviral signaling. Cytokine array gene expression and Ingenuity Pathway Analysis (IPA) helped evaluate changes in macrophage signaling in response to viral infection. TNFα-blocking antibodies and macrophages derived from Bai1-/- mice were used.Results: RAMBO treatment of mice reduced recruitment and activation of macrophages/microglia in mice with brain tumors, and showed increased virus replication compared with rHSVQ1. Cytokine gene expression array revealed that RAMBO significantly altered the macrophage inflammatory response to infected glioma cells via altered secretion of TNFα. Furthermore, we showed that BAI1 mediated macrophage TNFα induction in response to oHSV therapy. Intracranial inoculation of wild-type/RAMBO virus in Bai1-/- or wild-type non-tumor-bearing mice revealed the safety of this approach.Conclusions: We have uncovered a new role for BAI1 in facilitating macrophage anti-viral responses. We show that arming oHSV with antiangiogenic Vstat120 also shields them from inflammatory macrophage antiviral response, without reducing safety. Clin Cancer Res; 23(7); 1809-19. ©2016 AACR.
AB1016 The Change of Prevalence of Rheumatoid Arthritis and Osteoarthritis in Korea between 2011 and 2014: Table 1.
Authors: K.W. Moon
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) and Osteoarthritis (OA) are common arthritis in adults, and leading causes of disability. Estimating the prevalence of RA and OA is important for planning health care and public health systems. In South Korea, the Korean National Health Insurance (NHI) database has the medial and prescription claims data for most of Korean people. We evaluated the change of prevalence of RA and OA using NHI database between 2011 and 2014. <h3>Objectives</h3> The purpose of this study is to evaluate the prevalence and annual direct medical costs of rheumatoid arthritis and osteoarthritis in Korea. <h3>Methods</h3> We used data provided by Korean Health Insurance Research and Assessment agency. Identification of patients with RA and OA was based by main diagnostic code in database. The prevalence of RA and OA was evaluated in adults aged 20 years or older from 2011 to 2014. Annual direct medical costs per patient were also calculated. <h3>Results</h3> The prevalence of RA was decreased from 0.74% at 2011 to 0.68% at 2014. On the other hand, that of OA was increased from 7.96% at 2011 to 8.75% at 2014. Annual direct medical costs per patient tended to increase in both RA and OA, but rate of increase was greater in RA. In OA, annual direct medical costs were $226.86 at 2011, and increased up to $239.95 (105.8%). In RA, those were $209.95 at 2011, and increased up to $319.19 (152.0%). <h3>Conclusions</h3> The prevalence of RA was decreased, but that of OA was increased in Korea between 2011 and 2014. Annual direct medical costs per patient increased in both RA and OA, but rate of increase was greater in RA. <h3>References</h3> Lee TJ, Park BH, Son HK, et al. Cost of illness and quality of life of patients with rheumatoid arthritis in South Korea. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research 2012;15(1 Suppl):S43–9. Ma VY, Chan L, Carruthers KJ. Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain. Archives of physical medicine and rehabilitation 2014;95(5):986–95.e1. Sung YK, Cho SK, Choi CB, et al. Prevalence and incidence of rheumatoid arthritis in South Korea. Rheumatol Int 2013;33(6):1525–32. Sung YK, Cho SK, Choi CB, et al. Korean Observational Study Network for Arthritis (KORONA): establishment of a prospective multicenter cohort for rheumatoid arthritis in South Korea. Semin Arthritis Rheum 2012;41(6):745–51. Yu D, Peat G, Bedson J, et al. Annual consultation incidence of osteoarthritis estimated from population-based health care data in England. Rheumatology (Oxford, England) 2015;54(11):2051–60. <h3>Acknowledgement</h3> none declared <h3>Disclosure of Interest</h3> None declared
AB0436 All The “Hispanics” Are Not Equal. The Severity and Activity of Patients with SLE Is Higher in Mestizos Latin American vs. European Caucasian. Lessons from Relesser: Table 1
Authors: B. Hernández-Cruz, F. Alonso, J. Calvo Alén, J.M. Pego-Reigosa, F.J. Lόpez-Longo, M. Galindo Izquierdo, A. Olive, E. Tomero, Í. Rúa-Figeroa
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> SLE is a known disease for the study of ethnic and gender minorities. In Spain, from 1998 to 2011, occurred a significant immigration from Latin American people. The English speakers consider “Hispanics” as the same ethnic group. But there are differences between the Hispanics from Spain (with ethnicity European Caucasian) and the Hispanics from Latin America (with ethnicity Mestizo Latin American). <h3>Objectives</h3> To know the demographic, clinical, severity, activity, damage, mortality and comorbidity of SLE in Hispanics with ethnicity European Caucasian (EC) and in Hispanic Mestizos from Latin American (MLA) residents in Spain. To identify differences between the groups. <h3>Methods</h3> Design: observational, multicentric, crossover study. Patients with SLE (ACR 1987) and &lt;16 years old were included in 45 rheumatology Units in Spain. The RELESER methodology has been informed. Statistical analysis: we grouped the patients from the registry in two groups: EC and MLA and descriptive, univariate and multivariate statistics were done. <h3>Results</h3> 3,490 patients with SLE were included, 90% females; 3,305 (92%) Hispanics EC y 185 (5%) Hispanics MLA. The Table shows the main variables. Patients MLA had higher levels of activity (SLEDAI), severity (KATZ INDEX) and number of admissions to the hospital for SLE activity. The damage index (SLICC), mortality, and comorbidity Index showed no differences. In the multivariate analysis several models were constructed with adjusted for age, sex and disease duration. The patients MLA had a higher risk for Severity (Katz Index &gt;3) OR 1,45 (1,038 – 2, 026, p=0,02. This differences were not found for activity: OR 0,98 (0.30 - 1.66), may be for collinearity. <h3>Conclusions</h3> The SLE of Hispanics MLA patients had clinical differences when it was compared with Hispanics EC patients, mainly higher severity and activity. This shows that all the Hispanics are not equal. <h3>Disclosure of Interest</h3> None declared
Mutations of EZH2 In Myeloproliferative Neoplasms with Myelofibrosis: Correlation with Molecular and Clinical Data
Authors: Frank Stegelmann, Richard F. Schlenk, Martin Griesshammer, Peter Paschka, Carmen Blersch, Susanne Kuhn, Stefanie Schauer, Hartmut Döhner, Konstanze Döhner
Journal: Blood (2010)
3D Grown Human Placental-Derived Mesenchymal Stromal Cells (PLX-I) Support and Potentiate the Engraftment of Human Cord Blood Unfractionated (UFCBC) and Fractionated CD34+ Cells (hCD34+) in Irradiated NOD/SCID Mice.
Authors: Ora Burger, Osnat M. Jacov, Nirit D. Carmi, Galit F. Ashtamker, Lena Pinzur, Einat Mizrachi, Marina Rusanovsky, Noam Bercovich, Ofer B. Moshe, Limor Lior, Moran Meiron, William R. Prather, Shai Meretzki, Avi J. Treves, Avinoam Kadouri, Jacob M. Rowe, Edwin M. Horwitz, Arnon Nagler
Journal: Blood (2007)
SAT0144 Soluble Form of GP130 Molecule, An IL-6 Inhibitor, Contributes The Efficacy on RA To Tocilizumab (An Anti-IL-6 Receptor Antibody) Therapy
Authors: K. Yoshizaki, S.N.J. Song, H. Itoh, M. Iwahashi, K. Uno
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> IL-6, one of the causes of key molecule in RA pathogenesis, is signaling through the two receptor systems, one is IL-6 binding molecule (IL-6R) and the other is gp130 molecule (gp130), a signal transducer. And we know the presence of soluble form of IL-6 receptor (sIL-6R) and gp130 (sgp130). SIL-6R is an IL-6 functional accelerator; however less is known about the function of sgp130. <h3>Objectives</h3> We want to know whether sgp130 is a regulator of IL-6 both in vitro and vivo. Tocilizumab, an anti-IL-6 receptor antibody, shows good effect as well as TNF-a inhibitors for the treatment of RA. However the efficacy is variable to each of patient. We want to know the reason of this variety caused by sgp130 molecule. <h3>Methods</h3> [In vitro] Hep3B, a hepatoma derived cell line, was stimulated with IL-6 or Hyper IL-6 (complex of IL-6/sIL-6R) and co-cultured with tocilizumab or complex of gp130-Fc. CRP mRNA induction was accessed after two days culture by real-time RT-PCR. [In vivo] We performed with observation study. 88 RA patients (48 biologics naïve, 40 biologics non-naïve) were treated with tocilizumab over 16 weeks by every 4 week injection at dose 8mg/kg. 41 biologics in pretreatment serum was measured by Bio-Prex27 and Milliplex. The disease activity at 16 week was scored on DAS28-CRP. Multiple linear regression analysis were used to determine if any relationship existed between biologics and patient9s week 16 DAS 28-CRP score. <h3>Results</h3> [In vitro] Gp130-Fc did not inhibited the IL-6 induced CRP, however inhibited the Hyper IL-6 induced CRP productions. This means, gp130-Fc specifically inhibited the stimulation with complex of IL-6/sIL-6R which stimulation could not be inhibited with tocilizumab. [In vivo] 7 biomarker including sgp130 were predictive of the week 16 DAS28-CRP in naïve tocilizumab patients (R2=0.646, P&lt;0.0001) while gp130, GM-CSF, IP-10 were predictive in non-naïve patients (R2=0.486, P&lt;0.001). The most reliable marker is sgp130 (Estimated value -5.34). <h3>Conclusions</h3> 1) Sgp130 is a natural IL-6 inhibitor both in vitro and in vivo. 2) Higher level of sgp130 predicts the better outcome to tocilizumab therapy 3) Clinical efficacy might be resulted in the additive effects by the inhibition with tocilizumab (IL-6 binding inhibition on IL-6R) and the inhibition with sgp130, (IL-6/sIL-6R binding inhibition on gp130). 4) Prediction of individual RA patient9s outcome to tociizumab therapy can be recognized by measuring biologics including sgp130 (most reliable marker) in pretreatment serum. 5) Opening the personalized medicine in RA field by measuring biomarker before therapy. <h3>References</h3> non <h3>Disclosure of Interest</h3> None declared
PTH-056 Novel Model of Care: The Impact of A Combined IBD &amp; Antenatal Clinic
Authors: C Selinger, N Carey, G Ulivi, L Walker, F Shaikh, T Glanville
Journal: Gut (2016)

<h3>Introduction</h3> Care for pregnant women with IBD requires complex decision making weighing the risks and benefits of medication. Patients are often exposed to conflicting information from different health care professionals. This novel IBD antenatal clinic provides multidisciplinary care with an IBD clinician, an IBD nurse and an obstetrician all present during the consultation. <h3>Methods</h3> Prospective data collection for all patients attending the clinic from March 2014 to September 2015 included IBD diagnosis, treatment, adherence (MARS self report scale), disease &amp; pregnancy related patient knowledge (CCPKnow), course of pregnancy, mode of delivery and breast feeding. Patient satisfaction (1 not to 5 very satisfied) was ascertained by formal feedback weeks after delivery. <h3>Results</h3> Of 48 women (mean age 32 years; range 21–43) 27 had Crohn’s disease, 17 ulcerative colitis and 4 IBD-unclassified. Medication exposure during pregnancy included 5 ASA in 19, Thiopurines in 22 and anti-TNF in 11 cases (3 ongoing, 1 continued to birth, 7 stopped at mean week 25). Disease severity during pregnancy was remission in 62%, mild in 18%, moderate in 16% and severe in 4%. Poor medication adherence occurred in 5 of 27 patients providing adherence data. IBD investigations during pregnancy included 2 bowel ultrasound scans, 1 MRI and 2 sigmoidoscopies. Mean CCPKnow scores were 8.9 at 1 st consultation and 10.1 after birth. Two patients attended for pre-pregnancy counselling and 15 are currently pregnant. There were 27 (17 female) live births, 2 miscarriages, 1 intra-uterine death and 1 medically indicated termination for cardiac abnormalities. Delivery occurred on average at week 39 (range 29–41) with only 2 births before 35 weeks gestation. 19 (70%) patients had a vaginal delivery (5 assisted), 3 underwent elective and 5 emergency caesarean section. Average birth weight was 3099 gram (4 weighed less than 2500 g) and only 3 babies were on the 5 th percentile on personalised growth charts. 18 (66.6%) of mothers breastfed the infant. The average patient satisfaction score was 4.6. <h3>Conclusion</h3> This novel clinic model offers unique care for pregnant women with IBD. We have demonstrated very good IBD, obstetric and neonatal outcomes. Medication adherence was at least equivalent to non-pregnant patients. In contrast to previous studies showing high caesarean section and poor breast feeding rates in women with IBD our results were close to the national average for healthy women. As patient satisfaction was also high a wider adoption of the model should be considered. <h3>Disclosure of Interest</h3> C. Selinger Grant/research support from: Abbvie, Warner Chilcott, Consultant for: Abbvie, Warner Chilcott, MSD, Takeda, Speaker bureau with: Abbvie, Warner Chilcott, Dr Falk, Takeda, N. Carey: None Declared, G. Ulivi: None Declared, L. Walker: None Declared, F. Shaikh: None Declared, T. Glanville: None Declared
T Cells Expressing CD19-Specific Chimeric Antigen Receptors Are Inhibited By Indoleamine 2,3-Dioxygenase in Tumors
Authors: Soranobu Ninomiya, Leslie E Huye, Barbara Savoldo, Gianpietro Dotti, Helen E. Heslop, Malcolm K. Brenner, Cliona M Rooney, Carlos A. Ramos
Journal: Blood (2014)
Evaluation of Anti-Neoplastic Effects of a New Hemostatic Agent Ankaferd Blood Stopper on Myeloma Cell Line and Plasmocytoma Development in Balb/c Mice: Results of the First in Vitro and in Vivo Study
Authors: Ferit Avcu, Mustafa Guner, Muammer Misirci, Pinar Elci, Mukerrem Safali, Hakan Goker, Ibrahim Celalettin Haznedaroglu
Journal: Blood (2014)
Many US patients are hit with surprise emergency care bills, study finds
Authors: Michael McCarthy
Journal: BMJ (2016)

Roughly a fifth of insured US patients who obtained care at a hospital that was in their health plan’s network were potentially exposed to substantial “surprise bills” because they received treatment from emergency room staff who came from outside the network, a new study has found.1

Hospital physicians typically compete on the basis of quality and price to be included in health insurance plan networks, but many in-network hospitals contract out their emergency department care to groups of independent physicians who may or may not be …